DarioHealth Corp Dossier - Source-backed chat

DarioHealth Corp

DRIONASDAQ

SectorHealth Care

IndustryHealth Care Technology

Beta (adjusted)1.05

Intrinsic Value

No headline value published yetWe haven't published a headline intrinsic value for this company yet. Our data-reliability standards weren't met. Method estimates are shown for reference.

Market Price $6.16Price as of 1 Oct 2026

Data confidence Sign in to view data confidence

Market Cap $60.4M

Enterprise Value $84.8M

Shares Outstanding 10.8M diluted

Next Earnings Date12 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

DarioHealth Corp. (DRIO) is successfully executing a strategic pivot from non-recurring, low-margin revenue streams toward a highly scalable, high-margin B2B2C recurring revenue model. By leveraging its multi-condition digital therapeutics platform (covering diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health), Dario has built a robust channel partner ecosystem (including Solera Health and Amwell) that provides access to over 116 million covered lives. Despite near-term top-line headwinds from the non-renewal of a legacy Twill client, the underlying B2B2C business boasts sustained 80% non-GAAP gross margins. Coupled with aggressive operating expense reductions (down 21% YoY in Q1 2026), Dario is establishing strong operating leverage on its path toward cash flow breakeven by late 2026 to mid-2027.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets4 analysts · as of 18 Aug 2026

Low · most bearish analyst$8.00

Mean target$14.50

High · most bullish analyst$28.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 19 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

The bear case reflects potential delays in onboarding signed enterprise accounts, higher-than-expected customer churn, or intense price competition in the digital health and chronic care management space. If revenue recognition is deferred and cash burn remains elevated, the company may be forced to seek dilutive financing, delaying its cash flow breakeven target past 2027.

Base CaseCentral scenario

The base case assumes steady onboarding and conversion of the $12.9 million in contracted and late-stage ARR signed during the record 2025 sales season. Revenue growth is expected to accelerate in the second half of 2026 and into 2027. Operating expenses will continue to decline or stabilize due to AI-driven coaching efficiencies, allowing the company to reach cash flow breakeven by mid-2027. Valuation multiples are projected to expand as the market recognizes the high-margin recurring nature of the B2B2C business.

Bull CaseUpside scenario

DarioHealth's transition to a high-margin B2B2C recurring revenue model, supported by its comprehensive multi-condition AI platform, is driving significant operating leverage. With gross margins sustained at ~80% in its core business and a massive commercial pipeline of $127M, the company is on a clear path to cash flow breakeven by mid-2027. Furthermore, its clinical validation in the high-growth GLP-1 space and ongoing strategic alternatives review present substantial valuation upside compared to peers.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Highly scalable B2B2C model with sustained 80% non-GAAP gross margins.
Extensive distribution reach with access to over 116 million covered lives through blue-chip channel partners.
Comprehensive multi-condition platform addressing a massive $250 billion addressable market in chronic disease and mental health.
Proven clinical efficacy backed by over 100 peer-reviewed scientific studies, delivering up to a 5x ROI for payers.

Key Investment Risks

Execution and timing risks associated with converting contracted ARR and covered lives into active, revenue-generating users.
Near-term profitability challenges and ongoing cash burn prior to reaching the projected cash flow breakeven.
Intense competition from larger, well-capitalized digital health and telemedicine providers.
Potential customer concentration and churn risks within legacy or newly acquired portfolios.

Thesis Invalidation Triggers

A material delay in the cash flow breakeven timeline past the end of 2027.
Significant loss of key channel partnerships (e.g., Solera Health, Amwell) or failure to renew major health plan contracts.
A downward trend in B2B2C non-GAAP gross margins below 75%, indicating pricing pressure or escalating delivery costs.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.